Core Viewpoint - Hutchison China MediTech Limited (Chi-Med) announced that its drugs ELUNATE, ORPATHYS, and SULANDA will continue to be included in the updated National Medical Insurance Drug List effective from January 1, 2026, following a renewal agreement with the National Healthcare Security Administration of China. Additionally, TAZVERIK has been included in the inaugural National Commercial Health Insurance Innovative Drug List [1]. Group 1 - Chi-Med's drugs ELUNATE, ORPATHYS, and SULANDA will remain in the National Medical Insurance Drug List starting January 1, 2026 [1]. - The renewal agreement with the National Healthcare Security Administration ensures continued access to these medications for patients [1]. - TAZVERIK has been added to the first version of the National Commercial Health Insurance Innovative Drug List [1].

Core Viewpoint - Hutchison China MediTech Limited (00013) announced the renewal of its medical insurance agreements with the National Healthcare Security Administration of China, ensuring the continued inclusion of ELUNATE®, ORPATHYS®, and SULANDA® in the updated National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List effective from January 1, 2026 [1] Group 1 - ELUNATE®, ORPATHYS®, and SULANDA® will remain included in the National Medical Insurance Drug List starting January 1, 2026 [1] - TAZVERIK® has been included in the inaugural National Commercial Health Insurance Innovative Drug List [1]

Group 1 - The core announcement is that Hutchison China MediTech Limited (和黄医药) has successfully negotiated with the National Healthcare Security Administration of China to include its drugs, Elunate (爱优特), Orpathys (沃瑞沙), and Sulanda (苏泰达), in the new version of the National Medical Insurance Drug List effective from January 1, 2026 [1] - Tazverik (达唯珂) has been included in the inaugural National Commercial Health Insurance Innovative Drug List, indicating a significant step for the company's product portfolio in the commercial insurance sector [1]